Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Victor Ochola"'
Autor:
Micah Silaba, MMed, Michael Ooko, MSc, Christian Bottomley, PhD, Joyce Sande, MMed, Rachel Benamore, FRCR, Kate Park, FRCR, James Ignas, MD, Kathryn Maitland, FMedSci, Neema Mturi, MMed, Anne Makumi, MSc, Mark Otiende, MSc, Stanley Kagwanja, Dip MIS, Sylvester Safari, Dip MIS, Victor Ochola, BSc, Tahreni Bwanaali, MBA, Evasius Bauni, PhD, Fergus Gleeson, FRCR, Maria Deloria Knoll, PhD, Ifedayo Adetifa, PhD, Kevin Marsh, FMedSci, Thomas N Williams, FMedSci, Tatu Kamau, MPH, Shahnaaz Sharif, MD, Orin S Levine, PhD, Laura L Hammitt, MD, J Anthony G Scott, FMedSci
Publikováno v:
The Lancet Global Health, Vol 7, Iss 3, Pp e337-e346 (2019)
Summary: Background: Pneumococcal conjugate vaccines (PCV) are highly protective against invasive pneumococcal disease caused by vaccine serotypes, but the burden of pneumococcal disease in low-income and middle-income countries is dominated by pneum
Externí odkaz:
https://doaj.org/article/541affacefca48658490fc034546777d
Autor:
Thomas N. Williams, Anne Makumi, J. Anthony G. Scott, Rachel Benamore, Shahnaaz K Sharif, Orin S. Levine, Maria Deloria Knoll, Stanley Kagwanja, Sylvester Safari, Victor Ochola, Kathryn Maitland, Kate Park, Laura L. Hammitt, Tahreni Bwanaali, Kevin Marsh, Christian Bottomley, Ifedayo M. O. Adetifa, James Ignas, Micah Silaba, Neema Mturi, Michael Ooko, Tatu Kamau, Evasius Bauni, Fergus V. Gleeson, Joyce Sande, Mark Otiende
Publikováno v:
The Lancet. Global Health
The Lancet Global Health, Vol 7, Iss 3, Pp e337-e346 (2019)
e346
e337
The Lancet Global Health, Vol 7, Iss 3, Pp e337-e346 (2019)
e346
e337
Background Pneumococcal conjugate vaccines (PCV) are highly protective against invasive pneumococcal disease caused by vaccine serotypes, but the burden of pneumococcal disease in low-income and middle-income countries is dominated by pneumonia, most
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5509a270d1acdd5069ccf874a7749df4
https://doi.org/10.1016/s2214-109x(18)30491-1
https://doi.org/10.1016/s2214-109x(18)30491-1
Autor:
Micah Silaba, Michael Ooko, Christian Bottomley, Joyce Sande, Rachel Benamore, Kate Park, James Ignas, Kathryn Maitland, Neema Mturi, Anne Makumi, Mark Otiende, Stanley Kagwanja, Sylvester Safari, Victor Ochola, Tahreni Bwanaali, Evasius Bauni, Fergus Gleeson, Maria Deloria Knoll, Ifedayo Adetifa, Kevin Marsh, Thomas N Williams, Tatu Kamau, Shahnaaz Sharif, Orin S Levine, Laura L Hammitt, J Anthony G Scott
BackgroundPneumococcal conjugate vaccines (PCV) are highly protective against invasive pneumococcal disease caused by vaccine serotypes but the burden of pneumococcal disease in developing countries is dominated by pneumonia, most of which is non-bac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36fc3d995f9a05d1f8b97ae3a7f497eb